Competitor Analysis: TGF-? Inhibitors for Modulation of the Tumor Microenvironment
Competitor Analysis: TGF-? Inhibitors for Modulation of the Tumor Microenvironment
This industry report describes the competitive R&D landscape of specific TGF-beta inhibitors as well as TGF-beta receptor antagonists for modulation of the immunosuppressive tumor microenvironment as of December 2016.
The Competitor Analysis includes antibody-based inhibitors of transforming growth factor beta (TGF-beta) or antagonists of TGF-beta receptors as well as small molecule inhibitors of TGF-beta receptor tyrosine kinase. The report also covers cancer vaccines and engineered T-cells incorporating TGF-beta inhibition and novel RNA-based molecules inhibiting the production of TGF-beta.
Purchase of the pdf report includes a 6-month online access to the data of the report and any updates since the publication date as well as the clinical and preclinical combination studies. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
The report includes a compilation of currently active projects in research and development of TGF-beta/RTK inhibitors and TGF-betaR antagonists for modulation of the tumor microenvironment. In addition, the report lists company-specific R&D pipelines of TGF-beta inhibitors. Competitor projects are listed in a tabular format providing information on:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
This industry report describes the competitive R&D landscape of specific TGF-beta inhibitors as well as TGF-beta receptor antagonists for modulation of the immunosuppressive tumor microenvironment as of December 2016.
The Competitor Analysis includes antibody-based inhibitors of transforming growth factor beta (TGF-beta) or antagonists of TGF-beta receptors as well as small molecule inhibitors of TGF-beta receptor tyrosine kinase. The report also covers cancer vaccines and engineered T-cells incorporating TGF-beta inhibition and novel RNA-based molecules inhibiting the production of TGF-beta.
Purchase of the pdf report includes a 6-month online access to the data of the report and any updates since the publication date as well as the clinical and preclinical combination studies. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
The report includes a compilation of currently active projects in research and development of TGF-beta/RTK inhibitors and TGF-betaR antagonists for modulation of the tumor microenvironment. In addition, the report lists company-specific R&D pipelines of TGF-beta inhibitors. Competitor projects are listed in a tabular format providing information on:
- Drug Codes,
- Target/Mechanism of Action,
- Class of Compound,
- Company,
- Product Category,
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
1) TRANSFORMING GROWTH FACTOR BETA (TGF-?)/R INHIBITORS
Antibody-based TGF-? Inhibitors and TGF-? Receptor Antagonists
Small Molecule-Based TGF-? Receptor TK Inhibitors
Cancer Vaccines with TGF-? Inhibition
Engineered T-Cells & RNA with TGF-? Inhibition
2) CORPORATE TGF-? INHIBITOR R&D PIPELINES
Antibody-based TGF-? Inhibitors and TGF-? Receptor Antagonists
Small Molecule-Based TGF-? Receptor TK Inhibitors
Cancer Vaccines with TGF-? Inhibition
Engineered T-Cells & RNA with TGF-? Inhibition
2) CORPORATE TGF-? INHIBITOR R&D PIPELINES
